Plasma Cell Dyscrasias

1. Front Matter

   Pages i-vi

   PDF

2. Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma

   1. Front Matter

      Pages 1-1

      PDF

   2. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology

      • María-Victoria Mateos, Ola Landgren

      Pages 3-12

3. Multiple Myeloma

   1. Front Matter

      Pages 13-13

      PDF

   2. Vision Statement for Multiple Myeloma: Future Directions

      • Kenneth C. Anderson

      Pages 15-22

   3. Genomic Aberrations in Multiple Myeloma

      • Salomon Manier, Karma Salem, Siobhan V. Glavey, Aldo M. Roccaro, Irene M. Ghobrial

      Pages 23-34

   4. Epigenetics in Multiple Myeloma

      • Siobhan V. Glavey, Salomon Manier, Antonio Sacco, Karma Salem, Yawara Kawano, Juliette Bouyssou et al.

      Pages 35-49

   5. Role of Endothelial Cells and Fibroblasts in Multiple Myeloma Angiogenic Switch

      • Domenico Ribatti, Angelo Vacca

      Pages 51-61

   6. Targeting the Bone Marrow Microenvironment

      • Michele Moschetta, Yawara Kawano, Klaus Podar

      Pages 63-102

   7. Multiple Myeloma Minimal Residual Disease

      • Bruno Paiva, Ramón García-Sanz, Jesús F. San Miguel

      Pages 103-122

   8. Treatment of Newly Diagnosed Elderly Multiple Myeloma

      • Guillemette Fouquet, Francesca Gay, Eileen Boyle, Sara Bringhen, Alessandra Larocca, Thierry Facon et al.

      Pages 123-143

   9. Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

      • Jacob Laubach, Shaji Kumar

      Pages 145-167

   10. Treatment of Relapsed/Refractory Multiple Myeloma

       • Paola Neri, Nizar J. Bahlis, Claudia Paba-Prada, Paul Richardson

       Pages 169-194

   11. Treatment of MM: Upcoming Novel Therapies

       • Sagar Lonial

       Pages 195-205

   12. Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma

       • Susan J. Lee, Ivan Borrello

       Pages 207-225

   13. Transplantation for Multiple Myeloma

       • Yogesh S. Jethava, Frits van Rhee

       Pages 227-250

   14. Bone Disease in Multiple Myeloma

       • Homare Eda, Loredana Santo, G. David Roodman, Noopur Raje

       Pages 251-270

4. Primary Amyloidosis, Systemic Light Chain and Heavy Chain Diseases, Plasmacytoma

   1. Front Matter

      Pages 271-271

      PDF

   2. Immunoglobulin Light Chain Systemic Amyloidosis

      • Angela Dispenzieri, Giampaolo Merlini

      Pages 273-318

5. Waldenstrom’s Macroglobulinemia

   1. Front Matter

      Pages 319-319

      PDF

This book provides a concise overview of the state of the art in the biology and treatment of plasma cell malignancies, a heterogeneous group of diseases primarily characterized by the presence of clonal plasma cells within the bone marrow or extramedullary sites. The plasma cell dyscrasias investigated include monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, plasmacytoma, immunoglobulin deposition diseases (primary amyloidosis and systemic light and heavy chain deposition diseases), and Waldenström’s macroglobulinemia. In the case of multiple myeloma, the coverage ranges from genomic aberrations and microRNAs to treatment for different patient groups, upcoming novel therapies, immunotherapy, and transplantation. The book reflects the significant research advances achieved in this field during the past few years, which have enhanced our understanding of the molecular mechanisms responsible for the pathogenesis of plasma cell dyscrasias.

• Bone marrow microenvironment
• Genetics
• Multiple Myeloma
• Plasma cell dyscrasias
• Therapies

• Dept. of Medical Oncolgy/Hematology,, ASST-Spedali Civili di Brescia Dept. of Medical Oncolgy/Hematology,, Brescia, Italy

  Aldo M. Roccaro

• Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA

  Irene M. Ghobrial

Policies and ethics